sarilumab (Kevzara)
sarilumab is an FDA-licensed reference biologic from Sanofi-Aventis U.S. LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2017
Reference approved
Reference product
Kevzara sarilumab
Sanofi-Aventis U.S. LLC
- Approved
- May 22, 2017
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for sarilumab from the RCSB Protein Data Bank (PDB 8IOW).
Interactive biological assembly from PDB entry 8IOW. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for sarilumab, in chronological order.
Reference approval
Approval date of the reference sarilumab product.
9 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for sarilumab (Kevzara)?
No 351(k) biosimilars or interchangeable biosimilars referencing sarilumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.